NCT02889575

Brief Summary

Acute Renal Failure (ARF) is defined by a severe, and usually reversible, glomerular filtration rate decreasing. Acute Tubular Necrosis (ATN) remain the major cause of ARF involving distress and destruction of tubular cells. This specific typology of ARF may evolve toward Chronic Renal Failure (CRF) concretizing a major public health issue. Predict the progression of ARF towards CRF appears essential. The investigators believe that the PIIINP and urinary NGAL biomarkers may constitute robust biomarkers of progression risk towards CRF.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
287

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2012

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 24, 2016

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 5, 2016

Completed
Last Updated

September 7, 2016

Status Verified

August 1, 2016

Enrollment Period

2.5 years

First QC Date

August 24, 2016

Last Update Submit

September 5, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • PIIINP/Urinary Creatinine ratio levels between patients experimenting CRF or not.

    We expect to highlight different ratio PIIINP/Urinary Creatinine levels and evolution between patients experimenting CRF or not (defined less than 60 mL/min according MDRD formula).

    12months after initial diagnosis.

Secondary Outcomes (4)

  • NGAL/Urinary Creatinine ratio levels between patients experimenting CRF or not.

    12, 18 and 24 months after initial diagnosis.

  • Correlation between NGAL/Urinary Creatinine and PIIINP/Urinary Creatinine ratios among patients with ARF.

    3, 6, 12, 18 or 24 months after initial diagnosis.

  • Validation of high diagnostic performance of NGAL/Urinary Creatinine ratio to predict CRF occurrence.

    3, 6, 12, 18 or 24 months after initial diagnosis.

  • Validation of high diagnostic performance of PIIINP/Urinary Creatinine to predict CRF occurrence.

    3, 6, 12, 18 or 24 months after initial diagnosis.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients experimenting ARF in ATN context.

You may qualify if:

  • off-age patient.
  • ATN diagnosis based on 1) typical clinical environment (sepsis, nephrotoxicity...) 2) 50% decrease of glomerular filtration flow (according clearance MDRD) or more than 100micromol plasmatic creatinine increase. 3) no renal function improvement after efficient vascular filling (\>750cc normal saline or equivalent).
  • Consent.

You may not qualify if:

  • ARF not related with ATN context.
  • Life expectancy less than 3 months.
  • Protocol refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Acute Kidney InjuryKidney Tubular Necrosis, AcuteKidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesRenal Insufficiency, ChronicChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2016

First Posted

September 5, 2016

Study Start

April 1, 2012

Primary Completion

October 1, 2014

Study Completion

February 1, 2016

Last Updated

September 7, 2016

Record last verified: 2016-08